Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series

Eur J Intern Med. 2018 Nov:57:e11-e12. doi: 10.1016/j.ejim.2018.07.023. Epub 2018 Jul 31.

Authors

Alessandro Tomelleri¹, Corrado Campochiaro², Giacomo De Luca², Giulio Cavalli², Lorenzo Dagna²

Affiliations

¹ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: tomelleri.alessandro@hsr.it.
² Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.

PMID: 30076088
DOI: 10.1016/j.ejim.2018.07.023

No abstract available

Keywords: Immune checkpoint inhibitors; Leucocytoclastic vasculitis; Lung cancer; Vasculitis.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents, Immunological / adverse effects
Female
Humans
Lung Neoplasms / drug therapy*
Male
Middle Aged
Nivolumab / adverse effects*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Vasculitis, Leukocytoclastic, Cutaneous / chemically induced*
Vasculitis, Leukocytoclastic, Cutaneous / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor
Nivolumab
pembrolizumab